HC Wainwright Issues Pessimistic Forecast for SPRB Earnings

Spruce Biosciences, Inc. (NASDAQ:SPRB – Free Report) – HC Wainwright cut their FY2026 EPS estimates for Spruce Biosciences in a research note issued to investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($29.01) for the year, down from their prior forecast of ($23.32). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($30.05) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q4 2026 earnings at ($5.71) EPS, Q1 2027 earnings at ($4.35) EPS, Q2 2027 earnings at ($3.96) EPS, Q3 2027 earnings at ($2.58) EPS, Q4 2027 earnings at $0.32 EPS and FY2027 earnings at ($10.38) EPS.

Other analysts have also issued research reports about the company. Weiss Ratings raised Spruce Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Citigroup restated a “market outperform” rating on shares of Spruce Biosciences in a research report on Thursday, November 12th. Wall Street Zen upgraded Spruce Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 14th. The Goldman Sachs Group raised Spruce Biosciences to an “overweight” rating in a research note on Thursday, August 13th. Finally, Guggenheim reiterated a “buy” rating and issued a $104.00 price objective (down from $123.00) on shares of Spruce Biosciences in a report on Monday, August 17th. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Spruce Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $158.22.

Read Our Latest Stock Analysis on SPRB

Spruce Biosciences Stock Up 0.9%

Spruce Biosciences stock opened at $40.84 on Tuesday. Spruce Biosciences has a fifty-two week low of $38.06 and a fifty-two week high of $127.90. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.83 and a current ratio of 4.83. The firm has a 50 day moving average price of $46.24 and a 200 day moving average price of $53.71. The company has a market capitalization of $117.21 million, a PE ratio of -1.21 and a beta of 3.57.

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($8.51) EPS for the quarter, missing the consensus estimate of ($5.68) by ($2.83).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. SkyView Investment Advisors LLC purchased a new position in shares of Spruce Biosciences in the second quarter valued at approximately $162,000. Pale Fire Capital SE purchased a new stake in Spruce Biosciences during the 2nd quarter worth approximately $206,000. AWM Investment Company Inc. purchased a new stake in Spruce Biosciences during the 2nd quarter worth approximately $7,937,000. Bank of New York Mellon Corp acquired a new stake in Spruce Biosciences during the 2nd quarter worth approximately $366,000. Finally, Stempoint Capital LP acquired a new stake in Spruce Biosciences during the 1st quarter worth approximately $416,000. Hedge funds and other institutional investors own 91.71% of the company’s stock.

Key Headlines Impacting Spruce Biosciences

Investors following SPRB have been watching these headlines:

  • Neutral Sentiment: Spruce moved CRHX-101, formerly SPR-202/HBM9013, into Adrenyx Biosciences. The move is intended to advance the Harbour BioMed-originated antibody through a standalone company, but the announcement provided no details on the financial terms or how the separation affects Spruce shareholders. Article
  • Negative Sentiment: Coverage reported that Spruce shares fell following the spinout news, suggesting investors may be concerned about the implications of separating the program or the lack of clarity on shareholder economics. Article
  • Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS estimates, including deeper projected losses for several quarters, although it maintained a Buy rating. The repeated estimate-cut reports reflect a less favorable earnings outlook. Analyst estimate report

Spruce Biosciences Company Profile

(Get Free Report)

Spruce Biosciences is a biotechnology company focused on developing treatments for rare endocrine disorders. The U.S.-based company has concentrated on conditions with limited treatment options and has advanced oral drug candidates through clinical development. Its lead investigational candidate, tildacerfont, is a corticotropin-releasing factor type 1 receptor antagonist that Spruce studied for congenital adrenal hyperplasia, a rare disorder affecting hormone production. The company also evaluated the candidate for other endocrine conditions, including polycystic ovary syndrome.

Featured Articles

Earnings History and Estimates for Spruce Biosciences (NASDAQ:SPRB)

Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.